表紙
市場調查報告書

慢性阻塞性肺病(COPD):開發中產品分析

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 264708
出版日期 內容資訊 英文 555 Pages
訂單完成後即時交付
價格
Back to Top
慢性阻塞性肺病(COPD):開發中產品分析 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 555 Pages
簡介

慢性阻塞性肺病(COPD)是由於肺的呼氣吸氣不完全,呼吸困難造成的肺部疾病。由於空氣流入肺臟受阻,咳嗽,疲勞感,胸部疼痛的症狀便會與時俱增,同時也增加了併發症。第一個風險要素是吸煙,但化學物質及大氣污染等也是COPD惡化的要因。可以禁煙及服用其他治療藥來控制病情。

本報告提供慢性阻塞性肺病(COPD)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

慢性阻塞性肺病(COPD)概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

開發被休止的產品

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11743IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 9, 37, 13, 2, 81, 18 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Obstructive Pulmonary Disease (COPD) - Overview
    • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
    • AB Science SA
    • AB2 Bio Ltd
    • Adamis Pharmaceuticals Corp
    • Afimmune Biopharma Ltd
    • Aibios Co Ltd
    • AlgiPharma AS
    • Allinaire Therapeutics LLC
    • Amgen Inc
    • Angiocrine Bioscience Inc
    • apceth Biopharma GmbH
    • Apollo Therapeutics LLC
    • Aquilon Pharmaceuticals SA
    • Aridis Pharmaceuticals Inc
    • Ark Biosciences Inc
    • AstraZeneca Plc
    • AusBio Ltd
    • Avidin Ltd
    • Axolo Pharma Inc
    • Bai Shuo Beijing Pharmaceutical Technology Co Ltd
    • Bayer AG
    • BioMarck Pharmaceuticals Ltd
    • Boehringer Ingelheim International GmbH
    • C4X Discovery Holdings Plc
    • Celon Pharma SA
    • Chiesi Farmaceutici SpA
    • China Resources Pharmaceutical Group Ltd
    • Cipla Ltd
    • Circassia Pharmaceuticals Plc
    • Covenant Therapeutics LLC
    • CSL Ltd
    • Cureveda LLC
    • Cytokinetics Inc
    • Daewoong Pharmaceutical Co Ltd
    • Daiichi Sankyo Co Ltd
    • Denovo Biopharma LLC
    • Diffusion Pharmaceuticals Inc
    • Dimerix Ltd
    • Domainex Ltd
    • EmeraMed Ltd
    • EmphyCorp Inc
    • Emphymab Biotech LLC
    • Enterprise Therapeutics Ltd
    • EpiEndo Pharmaceuticals Ehf
    • Epitracker Inc
    • Errant Gene Therapeutics LLC
    • ethris GmbH
    • Evaxion Biotech ApS
    • Exotect LLC
    • F. Hoffmann-La Roche Ltd
    • Foresee Pharmaceuticals Co Ltd
    • Future Medicine Co Ltd
    • Galapagos NV
    • GeneFrontier Corp
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • Grifols SA
    • iCeutica Inc
    • Icure Pharmaceutical Inc
    • InMed Pharmaceuticals Inc
    • Inmunotek SL
    • Insmed Inc
    • Intech Biopharm Ltd
    • INVENT Pharmaceuticals Inc
    • Invion Ltd
    • JiangSu Qyuns Therapeutics Co Ltd
    • Johnson & Johnson
    • KBP BioSciences Co Ltd
    • Kither Biotech Srl
    • Koutif Therapeutics LLC
    • Kyowa Kirin Co Ltd
    • Liminal BioSciences Inc
    • LTT Bio-Pharma Co Ltd
    • Mariposa Health Ltd
    • Mereo Biopharma Group Plc
    • Meridigen Biotech Co Ltd
    • Metagone Biotech Inc
    • MetrioPharm AG
    • Naegis Pharmaceuticals Inc
    • NB Health Laboratory Co Ltd
    • Novabiotics Ltd
    • Novartis AG
    • Noveome Biotherapeutics Inc
    • Omnispirant Ltd
    • OncoArendi Therapeutics SA
    • Oncostellae SL
    • OPKO Health Inc
    • Orchid Pharma Ltd
    • Palo BioFarma SL
    • PharmaLundensis AB
    • Pharmaxis Ltd
    • Promedior Inc
    • Prous Institute for Biomedical Research SA
    • Pulmatrix Inc
    • Qu Biologics Inc
    • Quark Pharmaceuticals Inc
    • Re-Pharm Ltd
    • Regeneron Pharmaceuticals Inc
    • Resolys Bio Inc
    • Respiratorius AB
    • Rhizen Pharmaceuticals SA
    • Santhera Pharmaceuticals Holding AG
    • Silurian Pharmaceuticals Inc
    • Silver Valley Pharmaceutical Co Ltd
    • SolAeroMed Inc
    • sterna biologicals Gmbh & Co KG
    • Sulfateq BV
    • Sun Pharma Advanced Research Company Ltd
    • Symmune Therapeutics LLC
    • Synairgen Plc
    • Synovo GmbH
    • Syntrix Biosystems Inc
    • Taiho Pharmaceutical Co Ltd
    • TFF Pharmaceuticals Inc
    • TGV-Inhalonix Inc
    • Theratrophix LLC
    • Torrent Pharmaceuticals Ltd
    • Unity Biotechnology Inc
    • Verona Pharma Plc
    • Verra Therapeutics LLC
    • vTv Therapeutics Inc
    • Yungjin Pharm Co Ltd
    • Zai Lab Ltd
  • Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
  • Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apollo Therapeutics LLC, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquilon Pharmaceuticals SA, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals Inc, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ark Biosciences Inc, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AusBio Ltd, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Avidin Ltd, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H2 2019
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top